Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
We present a case of a premenopausal woman treated with GnRH agonist for a presumed uterine leiomyoma. This tumor reduced at first, but subsequent surgical specimens revealed a leiomyosarcoma. Magnetic resonance imaging (MRI), one of the most useful modalities for distinguishing between uterine leiomyoma and leiomyosarcoma, was undertaken twice, before GnRH agonist administration and then after 6 months of GnRH agonist administration. Apparent differences were observed between these MRI findings. Tumor-size reduction with GnRH agonist treatment does not always mean that the possibility of a leiomyosarcoma should be ruled out.
Kawamura
N
N
Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka, Japan. kawamuraog@med.osaka-cu.ac.jp
Iwanaga
N
N
Hada
S
S
Maeda
K
K
Sumi
T
T
Ishiko
O
O
Ogita
S
S
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001707:Biopsy, Needle; D002064:Buserelin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D007890:Leiomyosarcoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D017697:Premenopause; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D002064:Buserelin